Defence Therapeutics Inc (TSE:DTC) has released an update.
Defence Therapeutics Inc. announces a breakthrough in its pre-clinical trial for an anti-cancer vaccine, ARM-002, showing significant effectiveness against pancreatic cancer, particularly when used with an immune-checkpoint inhibitor. The promising results in animals, where treated subjects survived significantly longer with reduced tumor growth, suggest a potential new direction for Phase I trials in targeting this challenging and deadly disease. With pancreatic cancer being difficult to treat and often diagnosed late, Defence Therapeutics’ innovative approach could represent a major advancement in immunotherapy treatment options.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
